BCYCHIGH SIGNALOPERATIONAL10-K

BCYC has discontinued development of zelenectide pevedotin (BT8009) including its Phase II/III registrational trial Duravelo-2, while pivoting focus to nuzefatide pevedotin with a new Phase II pancreatic cancer trial launched in Q1 2026.

This represents a significant strategic pivot away from the company's most advanced program that was in registrational trials, suggesting either safety/efficacy concerns or strategic reprioritization. The shift to nuzefatide pevedotin in pancreatic cancer and new radioconjugate BT1702 indicates management is pursuing different therapeutic approaches, but investors face increased execution risk with earlier-stage assets replacing more mature programs.

Comparing 2026-03-17 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

BCYC's financials reflect the cash-intensive nature of biotech operations with R&D expenses growing substantially to $240.3M and operating cash flow declining meaningfully. The company's cash position decreased from $879.5M to $628.1M while total assets contracted 25% to $717.6M, though liabilities also decreased significantly by 34.3%. Despite the cash burn intensification, the company maintains a solid balance sheet with $628M in cash to fund operations, though the burn rate acceleration warrants close monitoring.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+90.3%
$1.2M→$2.4M

Capital expenditure jumped 90.3% — major investment cycle underway; assess returns on deployment.

Operating Cash Flow
Cash Flow
-51.6%
-$164.7M→-$249.7M

Operating cash flow fell 51.6% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
+38.9%
$173.0M→$240.3M

R&D investment increased 38.9% — signals commitment to future product development, though near-term margin impact.

Total Liabilities
Balance Sheet
-34.3%
$163.8M→$107.6M

Liabilities reduced 34.3% — deleveraging improves balance sheet strength and financial flexibility.

Net Income
P&L
-29.5%
-$169.0M→-$219.0M

Net income declined 29.5% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
-28.6%
$879.5M→$628.1M

Cash decreased 28.6% — monitor burn rate and upcoming capital needs.

Current Assets
Balance Sheet
-26.5%
$928.6M→$682.9M

Current assets declined 26.5% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-25%
$956.9M→$717.6M

Total assets contracted 25% — asset sales, write-downs, or balance sheet optimization underway.

Stockholders Equity
Balance Sheet
-23.1%
$793.1M→$610.0M

Equity decreased 23.1% — buybacks or losses reducing book value, monitor solvency ratios.

Operating Income
P&L
-17.7%
-$209.9M→-$247.1M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-02-25
ADDED
As of March 12, 2026, the registrant had 50,269,082 ordinary shares, nominal value 0.01 per share, and 19,437,944 non-voting ordinary shares, nominal value 0.01 per share, outstanding.
Our internal programs are focused on oncology indications with high unmet medical need.
Our product candidate, nuzefatide pevedotin, formerly BT5528, is a Bicycle Drug Conjugate, or a BDC molecule, whereby the Bicycle molecule is chemically attached to a toxin that, when administered, is cleaved from the Bicycle molecule and kills the tumor cells.
We are evaluating nuzefatide pevedotin, a BDC molecule targeting Ephrin type A receptor 2, or EphA2, in both an ongoing company-sponsored Phase I/II clinical trial to assess safety, pharmacokinetics and clinical activity in patients with advanced solid tumors and an ongoing company-sponsored Phase II clinical trial to evaluate the efficacy, safety and pharmacokinetics of nuzefatide pevedotin in adult patients with recurrent metastatic pancreatic ductal adenocarcinoma after progression on a first-line therapy, which commenced recruiting patients in the first quarter of 2026.
We are also developing BT1702, a Bicycle Radioconjugate, or BRC , molecule targeting Membrane Type 1 matrix metalloproteinase, or MT1-MMP, and carrying a lead-212, or 212 Pb, radioisotope payload for theranostic use.
We are currently conducting Investigational New Drug application, or IND, -enabling activities for BT1702.
We are also developing Bicycle Imaging Agents, or BIA molecules.
In a BIA molecule, a Bicycle molecule is linked to a chelated radiopharmaceutical imaging agent.
We are using BIA molecules to potentially derisk novel targets prior to further clinical development and to efficiently triage cancer indications for subsequent treatment with both BRC and BDC molecules.
Our discovery pipeline in oncology includes next-generation BDC molecules, BRC molecules and BIA molecules.
REMOVED
As of February 20, 2025, the registrant had 47,710,256 ordinary shares, nominal value 0.01 per share, and 21,492,099 non-voting ordinary shares, nominal value 0.01 per share, outstanding.
Our product candidates, zelenectide pevedotin, formerly BT8009, and BT5528, are each a Bicycle Toxin Conjugate, or a BTC molecule.
These Bicycle molecules are chemically attached to a toxin that, when administered, is cleaved from the Bicycle molecule and kills the tumor cells.
We are evaluating zelenectide pevedotin, a BTC molecule targeting Nectin-4, in both an ongoing company-sponsored Phase I/II clinical trial and an ongoing company-sponsored Phase II/III registrational trial called Duravelo-2, and enrollment in both of these trials are ongoing.
We are also evaluating BT5528, a BTC molecule targeting Ephrin type A receptor 2, or EphA2, in a company-sponsored Phase I/II clinical trial, for which enrollment is ongoing.
We are evaluating BT7480, a Bicycle TICA molecule targeting Nectin-4 and agonizing CD137, in a company-sponsored Phase I/II clinical trial.
Our discovery pipeline in oncology includes next-generation BTC molecules and Bicycle Radionuclide Conjugates, or BRC molecules.
In August 2024, we focused our research and development pipeline on clinical programs and research areas that we believe have the highest potential to maximize value creation and we consolidated all discovery research activities to our headquarters in Cambridge, U.K.
Moving forward, we will prioritize the clinical development of BTC molecules in multiple tumor types; focus near-term research efforts on advancing our BRC pipeline and the discovery of next-generation BTC molecules; and, except for BT7480, explore innovative ways to continue development of our immuno-oncology portfolio, including Bicycle TICA molecules, through collaboration.
From our founding through December 31, 2024, we have generated substantial intellectual property, including 10 patent families directed to novel scaffolds, linkers and payloads, 10 patent families directed to our platform technology, 48 patent families directed to bicyclic peptides and related conjugates, and 21 patent families directed to later inventions relating to such bicyclic peptides and related conjugates, such as methods of making or using certain bicyclic peptide conjugates for treating various indications.
MORE OPERATIONAL SIGNALS
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NVDAHIGHNVIDIA has repositioned itself from a "full-stack computing infrastructure compa...
2026-02-25
NOWHIGHServiceNow has fundamentally repositioned itself as an AI-first platform company...
2026-01-29
TSLAHIGHTesla has fundamentally repositioned itself from an electric vehicle company to ...
2026-01-29
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →